Bioinformatics, cheminformatics, and molecular docking/dynamics studies assessing pioglitazone and telmisartan as repurposed PPARG agonists for treating NSCLC with a targeted delivery system was done. This evidence concerns the gene PPARG and non-small cell lung carcinoma.